{"url_path":"/sec/cik-0001567892/8-k/2026-06-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ****Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1567892/0001104659-26-073787-index.html","accession_number":"0001104659-26-073787","cik":"0001567892","ticker":null,"issuer_name":"Keenova Therapeutics plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1567892/0001104659-26-073787-index.html","primary_entity_key":"0001567892","primary_entity_name":"Keenova Therapeutics plc"},"word_count":599,"has_tables":true,"body_markdown":"**Item 9.01****Financial Statements and Exhibits.**\n\n \n\n(d) *Exhibits*\n\n \n\n**Exhibit\nNumber**\n \n**Description**\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n \n\n**Information Regarding Forward-Looking Statements**\n\n \n\nThis Current Report on Form 8-K includes “forward-looking\nstatements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform\nAct of 1995. Forward-looking statements may be identified by the use of words such as “continue,” “guidance,”\n“expect,” “outlook,” “project,” “believe” or other similar expressions that predict or\nindicate future events or trends or that are not statements of historical matters. Forward looking statements in this Current Report\ninclude statements regarding the expected timing for the closing of the transaction and the expected total consideration. These statements\nare based on various assumptions, whether or not identified in this communication, and on current expectations and are not predictions\nof actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as,\nand must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability.\nActual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances\nare beyond the control of Keenova. These forward-looking statements are subject to a number of risks and uncertainties, including the\ntiming, receipt and terms and conditions of any required governmental and regulatory approvals of the proposed transaction that could\ndelay the consummation of the proposed transaction; the occurrence of any event, change or other circumstances that could give rise to\nthe termination of the purchase agreement entered into in connection with the proposed transaction; the risk that the parties to the\npurchase agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all; risks related\nto disruption of management time from ongoing business operations due to the proposed transaction; the risk that any announcements relating\nto the proposed transaction could have adverse effects on the value of Keenova’s ordinary shares; the risk of any unexpected costs\nor expenses resulting from the proposed transaction; the performance of the Business and its ability to generate gross profits following\nthe closing of the transaction and other risks and uncertainties affecting Keenova, including those described from time to time under\nthe caption “Risk Factors” and elsewhere in Keenova’s Securities and Exchange (“SEC”) filings and reports,\nincluding Keenova’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on April 15,\n2026. These filings, when available, are available on the investor relations section of the Keenova website at https://investor.keenova.com/\nor on the SEC’s website at https://www.sec.gov. If any of these risks materialize or any of these assumptions prove incorrect,\nactual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that\nKeenova presently does not know of or that Keenova currently believes are immaterial that could also cause actual results to differ from\nthose contained in the forward-looking statements. The forward-looking statements included in this current report are made only as of\nthe date hereof. Keenova assumes no obligation and does not intend to update these forward-looking statements, except as required by\nlaw.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly\nauthorized.\n\n \n\n \n**KEENOVA THERAPEUTICS PLC**\n\n \n \n \n\nDate:  June 15, 2026\nBy:\n /s/ Mark Tyndall\n\n \nName:\nMark Tyndall\n\n \nTitle:\n*Executive Vice President, Chief Legal Officer &\nCorporate Secretary*"}